sparfloxacin has been researched along with amoxicillin-potassium clavulanate combination in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubier, M; Gialdroni-Grassi, G; Hosie, J; Huchon, G; Legakis, N; Lode, H; Regamey, C; Segev, S; Tolstuchow, N; Vester, R; Wijnands, WJ | 1 |
| Allegra, L; Guyen, JN; Hosie, J; Konietzko, N; Leophonte, P; Pauwels, R; Petitpretz, P | 1 |
| Davies, BI; Dirks-Go, SI; Hoogkamp-Korstanje, JA; Kabel, P; Manson, WL; Stobberingh, EE; Vreede, RW | 1 |
| Goss, TF; Najib, MM; Stein, GE | 1 |
2 trial(s) available for sparfloxacin and amoxicillin-potassium clavulanate combination
| Article | Year |
|---|---|
Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Clavulanic Acids; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Penicillins; Pneumonia, Bacterial; Quinolones; Streptococcus pneumoniae | 1996 |
Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study.
Topics: Acute Disease; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Fluoroquinolones; Haemophilus influenzae; Humans; Lung Diseases, Obstructive; Middle Aged; Moraxella catarrhalis; Quinolones; Streptococcus pneumoniae | 1996 |
2 other study(ies) available for sparfloxacin and amoxicillin-potassium clavulanate combination
| Article | Year |
|---|---|
Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Clavulanic Acids; Drug Evaluation; Drug Therapy, Combination; Fluoroquinolones; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Quinolones; Streptococcus pneumoniae | 1997 |
Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Azithromycin; Cefaclor; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Erythromycin; Fluoroquinolones; Humans; Models, Economic; Outpatients; Pneumonia; Treatment Outcome | 2000 |